HC Wainwright & Co. Maintains Neutral on Zymeworks, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Neutral rating on Zymeworks while raising the price target from $10 to $12, indicating a slightly more optimistic outlook.
September 25, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Neutral rating on Zymeworks but raised the price target from $10 to $12, suggesting a slightly more positive outlook on the stock.
The increase in the price target from $10 to $12 by HC Wainwright & Co. suggests a more optimistic view on Zymeworks' future performance, which could positively influence investor sentiment and potentially lead to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100